METEORA-II: MEtronomic TrEatment Option in Advanced bReast cAncer

Sponsor

ETOP IBCSG Partners Foundation (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT02954055

Collaborator

(none)

140

Enrollment

Locations

Arms

53.6

Anticipated Duration (Months)

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a multi-center, randomized phase II trial that will randomise women with ER-positive, HER2-negative (Human Epidermal Growth factor Receptor 2-negative) metastatic or locally relapsed breast cancer in a ratio of 1:1 to receive a metronomic regimen of vinorelbine plus cyclophosphamide and capecitabine, or the conventional paclitaxel monotherapy.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer	Drug: Paclitaxel Drug: Cyclophosphamide Drug: Capecitabine Drug: Vinorelbine	Phase 2

Detailed Description

The prognosis for patients with locally advanced or metastatic disease (ABC) remains poor, with a median survival of 2-4 years. About 10% of newly diagnosed BC patients present with ABC, and 30% to 50% of patients diagnosed at earlier stages will subsequently develop metastatic disease.

In the first-line treatment of HER2 (Human Epidermal Growth factor Receptor 2) negative ABC patients, various chemotherapy regimens can be used including taxanes, which are among the most active agents in BC. Single agent response rates range from 20 to 50%. However, eventually all patients will progress with a median time to progression of 5 to 7 months. A weekly (qw) over a three-weekly (q3w) administration schedule of paclitaxel has been shown to be more effective in the metastatic as well as in the adjuvant setting after standard chemotherapy

The VEX regimen was recently investigated within a phase II trial currently ongoing at the European Institute of Oncology (IEO) (IEO number IEOS582/111; EudraCT Number: 2010-024266-21; title: "A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine and vinorelbine in metastatic breast cancer patients"). Patients received vinorelbine 40 mg orally on days 1, 3 and 5 every week, cyclophosphamide 50 mg daily and capecitabine 500 mg 3 times a day.

Given the promising activity of the VEX regimen in a pre-treated population of advanced breast cancer patients and the good tolerability, the aim of the present trial is to investigate whether the VEX schedule may improve efficacy and tolerability as compared to standard paclitaxel treatment in advanced or metastatic ER-positive/HER2-negative breast cancer patients.

The concept of the VEX metronomic treatment is to administer the combination for as long as the patient has the possibility of deriving a benefit from it. The time to treatment failure (TTF) has been chosen as primary endpoint for this trial. TTF is defined as time from the date of randomization to the date when the final dose of trial treatment is administered. Chemotherapy may need to be stopped due to lack of tolerability, lack of efficacy or patient preference through subjective symptom assessment. TTF is a composite endpoint combining all these feasibility aspects of a treatment. It is therefore uniquely suited to the research question of the current trial. The secondary endpoints progression-free survival, disease control and safety will allow further assessment of the feasibility of the VEX metronomic treatment versus the paclitaxel monotherapy regimen.

Study Design

Study Type:

Interventional

Actual Enrollment :

140 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide and Capecitabine (VEX) Versus Weekly Paclitaxel as First-line or Second-line Treatment in Patients With ER-positive/HER2-negative Advanced or Metastatic Breast Cancer

Actual Study Start Date :

Sep 13, 2017

Anticipated Primary Completion Date :

Dec 1, 2021

Anticipated Study Completion Date :

Mar 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Arm A Paclitaxel 90 mg/m2 days 1, 8, 15 q4w. Patients will continue to receive assigned treatment until progression or lack of tolerability.	Drug: Paclitaxel Arm A Other Names: Paclitaxel Sandoz
Experimental: Arm B Metronomic VEX: Cyclophosphamide 50 mg orally once daily continuously, Capecitabine 500 mg, orally 3 times a day (1500 mg/day) continuously, Vinorelbine 40 mg orally days 1, 3, 5 each week continuously. Patients will continue to receive assigned treatment until progression or lack of tolerability.	Drug: Cyclophosphamide Arm B Other Names: Endoxan Baxter Drug: Capecitabine Arm B Other Names: Xeloda Drug: Vinorelbine Arm B Other Names: Navelbine

Arm

Intervention/Treatment

Active Comparator: Arm A

Paclitaxel 90 mg/m2 days 1, 8, 15 q4w. Patients will continue to receive assigned treatment until progression or lack of tolerability.

Drug: Paclitaxel

Arm A

Other Names:

Paclitaxel Sandoz

Experimental: Arm B

Metronomic VEX: Cyclophosphamide 50 mg orally once daily continuously, Capecitabine 500 mg, orally 3 times a day (1500 mg/day) continuously, Vinorelbine 40 mg orally days 1, 3, 5 each week continuously. Patients will continue to receive assigned treatment until progression or lack of tolerability.

Drug: Cyclophosphamide

Arm B

Other Names:

Endoxan Baxter

Drug: Capecitabine

Arm B

Other Names:

Xeloda

Drug: Vinorelbine

Arm B

Other Names:

Navelbine

Outcome Measures

Primary Outcome Measures

Time to treatment failure (TTF) compared between treatment groups. [From date of randomization until the date the final dose of trial treatment was given due to documented progression, lack of tolerability or until further treatment is declined, assessed up to 36 months from enrollment of the first patient.]
Efficacy and tolerability, measured by time to treatment failure, of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) versus weekly paclitaxel, using an intent-to-treat analysis approach.

Secondary Outcome Measures

Frequency of targeted adverse events (safety and tolerability). [Time from day 1 of cycle 1 until 28 days after stopping trial treatment.]
Frequency of adverse events by type and worst grade experienced.
Disease control [From date of randomization until the date of first documented progression, assessed up to 36 months from enrollment of the first patient.]
Best overall response of complete response (CR) or partial response (PR), or stable disease (SD) lasting for at least 24 weeks, measured from randomisation to progression.
Progression free survival (PFS) [Time from randomization until documented disease progression, assessed up to 36 months from the enrollment of the first patient.]
Distribution of PFS for each treatment group using Kaplan-Meier; median PFS with two-sided 95% confidence interval (CI). PFS according to RECIST 1.1 criteria or death, whichever occurs first.
Overall Survival [From day 1 of cycle 1 until death from any cause (censored at date of last assessment of vital status for patients lost to follow up), assessed up to 36 months from the enrollment of the first patient.]
Overall survival from time of randomisation will be summarised for each treatment group.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically or cytologically confirmed HER2-negative locally advanced or metastatic (stage IV) breast cancer.
Maximum of one prior line of chemotherapy for advanced or metastatic breast cancer.
Measurable or non-measurable, but radiologically evaluable (except for skin lesions), disease according to RECIST 1.1 criteria.
Female aged 18 years or older.
Life expectancy > 3 months.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
ER-positive disease by local laboratory, determined on most recent available tissue (latest biopsy of metastatic lesion, otherwise prior biopsy or surgical specimen).
If previously treated with a taxane in the neoadjuvant or adjuvant setting, the period from end of treatment to disease recurrence must have been > 12 months (> 365 days).
Radiation therapy, if given and regardless of site, must be completed at least 2 weeks prior to randomization.
Normal hematologic status,
Absolute neutrophil count ≥1000/mm3 (1.0 × 109/L),
Platelets ≥ 100 × 109/L,
Hemoglobin ≥ 9 g/dL (≥ 90 g/L).
Normal renal function: serum creatinine ≤ 1.5 ULN or calculated creatinine clearance ≥ 50 mL/min according to the Cockcroft-Gault formula.
Normal liver function:
Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (< 3 × ULN) is allowed.
Aspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 3 × ULN; if the patient has liver metastases, ALT and AST must be ≤ 5 × ULN.
Women of child bearing potential must have documented negative pregnancy test within 2 weeks prior to randomization and agree to acceptable birth control (non-hormonal) during and up to 6 months after trial therapy.
Written Informed Consent (IC) must be signed and dated by the patient and the Investigator prior to starting screening procedures and randomization.
The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.

Exclusion Criteria:

More than one prior line of chemotherapy for advanced or metastatic breast cancer
Previous treatment for advanced or metastatic disease with taxanes, or capecitabine or vinorelbine or oral cyclophosphamide.
More than 2 lines of previous endocrine therapy for locally advanced or metastatic breast cancer.
Known active central nervous system metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with history of Central Nervous System (CNS) metastases or spinal cord compression are eligible if they are clinically and radiologically stable for at least 4 weeks before first dose of trial treatment and have not required high-dose steroid treatment in the last 4 weeks).
Peripheral neuropathy grade 2 or higher (CTCAE version 4.0).
Significant uncontrolled cardiac disease (i.e. unstable angina, myocardial infarction within prior 6 months), patients classified as having a New York Heart Association (NYHA) class III or IV congestive heart failure.
Pregnant or lactating.
Prior history of non-breast malignancy (except for adequately controlled basal cell carcinoma of the skin, carcinoma in situ of the cervix, in situ carcinoma of the bladder).
Any concurrent condition which in the Investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol.
Contraindications or known hypersensitivity to the trial medication or excipients.
The use of any anti-cancer investigational agents within 30 days prior to expected start of trial treatment.

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Centro di Riferimento Oncologico (CRO)	Aviano	Italy
2	A.O.U. di Bologna Policlinico S. Orsola-Malpighi Viale Ercolani 4/2	Bologna	Italy	40138
3	Ospedale di Bolzano Oncologia Medica Via lorenz Bohler 5	Bolzano	Italy	39100
4	Aziendale Spedali Civili di Brescia SSVD Breast Unit P.le Spedali Civili 1	Brescia	Italy	25123
5	"Antonio Perrino" Division of Medical Oncology Strada Statale 7 APPIA	Brindisi	Italy	72100
6	Candiolo Cancer Institute (FPO-IRCCS)	Candiolo	Italy
7	ASST Di Cremona, Unità di Patologia Mammaria-Breast Unit VIALE CONCORDIA 1	Cremona	Italy	26100
8	Ospedale Misericordia di Grosseto	Grosseto	Italy
9	ASST Ovest Milanese Oncology Department Via Papa Giovanni Paolo II	Legnano	Italy
10	Ospedale Generale Provinciale di Macerata	Macerata	Italy
11	IRST IRCCS Division of medical oncology Via Maroncelli 40	Meldola	Italy	47014
12	Istituto Europeo di Oncologia, Division of Medical Senology, Via Ripamonti 435	Milano	Italy	20141
13	Osp. Sacro Cuore Don Calabria Division in Medical Oncology	Negrar	Italy
14	Istituti Clinici Scientifici Maugeri SpA SB	Pavia	Italy
15	Ospedale S. Maria delle Croci	Ravenna	Italy
16	Ospedale Infermi Uo Oncologia Via Settembrini 2	Rimini	Italy	47923
17	Fondazione Policlinico Universitario A.Gemelli	Rom	Italy
18	A.O.U Città della Salute e della Scienza di Torino SSCVD Oncologia Medica Senologica (Oncology Dep.- Breast Unit) Via Cherasco 23	Torino	Italy	10126
19	Asst Bg Ovest Ospedale Di Treviglio	Treviglio	Italy
20	ASST Settelaghi - Ospedale di Circolo e Fondazione Macchi U.O Oncologia Medica Viale L. Borri, 57	Varese	Italy	21100